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GERALD A. BEATHARD
Austin Diagnostic Clinic, Austin, Texas, USA
Mechanical versus pharmacomechanical thrombolysis for the treat-
ment of thrombosed dialysis access grafts. Pharmacomechanical throm-
bolysis offers the first practical approach for non-surgical therapy of
thrombosed dialysis access grafts. This technique involves both lysis
using a fibrinolytic enzyme and mechanical maceration of the clot. The
technique can be accomplished in a short period of time, has a high
degree of success and has a low level of complications. To evaluate the
effectiveness of the mechanical aspects of this technique used alone
without the lytic enzyme, a study was designed in which 103 cases of
thrombosed PTFE grafts were randomly assigned to either a mechani-
cal (M) group consisting of 55 cases or a pharmacomechanical (PM)
group consisting of 48 cases. Both groups were treated in an identical
manner using crossed pulse-spray catheters, except that in the M group
heparinized saline was used as the pulsing agent while in the PM group
concentrated urokinase was used. The two groups were completely
comparable in all other respects. The combined procedure of throm-
bolysis and angioplasty was successful in restoring flow in 92.8% of the
M group and 93.8% of the PM group. Life table analysis revealed 74%,
65%, 58% and 37% function in the M group at 15, 30, 60 and 90 days,
respectively. The rates for the PM group at the same time intervals were
77%, 72%, 62% and 46%. In none of these parameters was there any
significant difference between the two groups. The mean time required
for the procedure in the M group was shorter because of the time delay
between pulses of enzyme in the PM group built into the technique
which was used. Only local complications were seen in either group and
consisted of small hematomas at previous needle puncture sites. There
was no significant difference between the two groups in this regard. It is
concluded that mechanical thrombolysis using saline pulses generated
by crossed pulse-spray catheters followed by balloon maceration and
dilation is a safe technique and is as effective as pharmacomechanical
thrombolysis for the treatment of thrombosed dialysis access grafts.
A patent vascular access is critical to the treatment of the
chronic hemodialysis patient. When patency is lost, restoration
of function is urgent. An inability to perform dialysis in a timely
manner is a critical problem that can result in patient morbidity
and mortality. When presented with a patient having a throm-
bosed vascular access graft, most nephrologists have only two
choices, either send the patient to surgery or insert a central
venous dialysis access catheter. Either choice may be associ-
ated with problems. The first frequently results in an inordinate
delay in dialysis and perhaps a period of hospitalization while
exposing the patient to the risks of pain, blood loss and possible
infection. The second is associated with the immediate and
long-term risks of infection, less than optimum dialysis, and the
possibility of central venous stenosis. The ideal solution would
be the availability of a rapid, safe, effective and minimally
invasive out-patient procedure for the restoration of graft
function, a technique that could be applied by the nephrologist
and allow the patient to be quickly returned to the dialysis unit
for timely effective treatment. Throinbolysis has been studied
for the past 20 years as a possible candidate for this role [1—13].
Until recently, a practical approach to thrombolysis in the
dialysis patient has been an elusive goal. Various techniques
have been attempted, but there have been major problems and
the results have frequently been discouraging. Early attempts
used protocols that required prolonged infusion of large doses
of the lytic enzyme. Patients often required hospitalization for
several days, bleeding complications were common, there was
risk of allergic reactions to the enzyme, and the rate of success
was disappointingly low [1—91.
Recently, a thrombolysis technique has been developed
incorporating a combination of enzyme lysis with urokinase
administered using pulse-spray catheters followed by mechan-
ical maceration and removal of the clot. This approach, referred
to as pharmacomechanical thrombolysis, is the first to prove
practical for use in the dialysis patient. Using this combination
of pharmacological and mechanical factors, over 98% of cases
can be successfully treated within one to two hours with a very
low incidence of side effects [10—13].
This study was undertaken in order to determine the effec-
tiveness of the mechanical aspects of pharmacomechanical
thrombolysis used alone in the treatment of thrombosed dialysis
access grafts without the presence of the pharmacologically
active lytic enzyme.
Methods
Design of the study
Only dialysis patients having thrombosed polytetrafluroeth-
ylene (PTFE) vascular access grafts were entered into the
study. Either an infected graft or the presence of a contraindi-
cation to the use of fibrinolytic agents were disqualifications for
the study. After giving informed consent, the patients were
randomly assigned to either the pharmacomechanical (PM) or
the mechanical (M) groups. A computer generated table of
random numbers was used for this purpose. Patients with an
odd number were assigned to the PM group and those with an
even number were assigned to the M group. Each episode of
thrombosis treated with thrornbolysis in a patient having re-
peated episodes was treated as a separate case for the purposes
of the study. Both groups were treated in a similar fashion
except that in the M group heparinized saline was used as the
pulsing agent to produce mechanical clot lysis and in the PM
group concentrated urokinase was used. Both groups were
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Table 1. Thrombolysis technique
Graft entered with needle in up-stream direction
Straight graft—adjacent to arterial anastamosis
Loop graft—low on venous side of loop
Guide wire (glide) passed up to level of superior vena cava
Pulse-spray catheter inserted and passed up to central vein
Used to inject medications and perform a venogram
If severe venous or anastamotic stenosis present
Pulse-spray catheter removed and replaced with angioplasty
catheter
Stenosis dilated
Pulse-spray catheter replaced
Otherwise, continue
Insert occlusion wire into pulse-spray catheter and attach valve
assembly
Graft entered with needle in down-stream direction
Adjacent to venous anastamosis—straight or loop graft
Guide wire (glide) passed through graft and across arterial
anastamosis
Pulse-spray catheter inserted and passed to but not across arterial
anastamosis
Insert occlusion wire into pulse-spray catheter and attach valve
assembly
Pulse with agent (saline or urokinase)
Remove pulse-spray catheters
Use angioplasty balloon throughout entire graft
Macerate residual clot
Dilate areas of stenosis
Insert embolectomy balloon at venous anastamosis site—through a
sheath
Down stream direction across arterial anastamosis
Pull back across anastamosis—gently
Pull back through entire graft—vigorously
Flush venous end of graft with saline
Angioplasty of any remaining venous stenosis lesion
Verify patency and internal appearance with venogram
Remove all objects from graft and obtain hemostasis (thrombin
gelatin sponge)
evaluated for effectiveness and safety of the procedure in the
immediate and long-term time periods.
Thrombolysis technique
The same basic technique was used in both groups for
thrombolysis (Table 1) and was similar to that described by
Bookstein and Valji [121, the major difference being the period
of time between pulses of lytic enzyme (see below). First, a thin
wall needle (Baxter Healthcare Corp., Round Lake, Illinois,
USA) was inserted into the graft. In straight grafts the insertion
point was approximately 4 cm above the arterial anastamosis in
a downstream direction (toward the venous anastamosis). In
loop grafts the needle was placed low on the venous side of the
loop, just beyond the curve of the ioop. A 150 cm straight guide
wire (glide wire, Medi-Tech Inc.) was passed through the
needle and, if possible, up to the level of the superior vena cava.
Thrombolysis was not attempted unless a guide wire could be
passed through the thrombosed graft and across any area of
stenosis within the graft or the draining veins. This was neces-
sary to assure that flow could be established once the clot was
lysed. Cases in which a wire could not be passed were dropped
from the study and were not used in any comparisons or
calculations.
Once the guide wire was in place, the opening was dilated
using a SF dilator. A pulse-spray catheter (Angio Dynamics
Inc.) with a 10 cm infusion length was then passed over the wire
and advanced as far as the length of the catheter (40 cm) would
permit or until the superior vena cava was reached. This was
used as a straight catheter to inject medications and to perform
a venogram. Each patient was given 5,000 U of heparin, 1 g of
cephazolin (Squibb, Princeton, New Jersey, USA) and midazo-
lam hydrochloride (Versed, Hoffman-LaRoche, Research Tri-
angle Park, North Carolina, USA) for sedation. The venogram
was performed to identify areas of stenosis and to determine the
extent of the thrombosis as the catheter was slowly withdrawn
back into the graft. If venous stenosis was found, the pulse-
spray catheter was removed and replaced with an angioplasty
catheter. The lesion was dilated using a standard technique [121
and the pulse-spray catheter was replaced.
This venous pulse-spray catheter was positioned so that the
tip of the catheter was at the venous anastamosis. The thin wall
needle was then inserted approximately 4 cm from the venous
anastamosis in both straight and ioop grafts pointing in an
upstream direction (toward the arterial anastamosis). The guide
wire was passed up to and across the arterial anastamosis. After
using a SF dilator to dilate the opening, the second pulse-spray
catheter was inserted and positioned so that the tip was at the
arterial anastamosis. The infusion length of this arterial pulse-
spray catheter used in straight grafts was 10 cm; a 20 cm length
was used in loop grafts. Both catheters were 40 cm in overall
length and had a 1.5 cc fill volume. With the two catheters
placed in this crossed fashion the entire length of the graft could
be covered.
These catheters are supplied with an occlusion wire to
occlude the distal tip of the catheter and a dual check valve with
Y-connector to facilitate the administration of the lytic agent.
These were attached and the two systems were connected using
a special bifurcated line (Angio Dynamics) to permit simulta-
neous injection into both catheters. A 1 ml syringe was used to
administer the lytic agent. In the PM group 250,000 IU of
urokinase (Abbott) in 10 ml containing 4,000 U of heparin was
used as the lytic agent. The total fill-volume of the catheters is
3 cc (1.5 cc each), this amount of urokinase was injected to
prime the catheters and then they were pulsed. Repeated pulses
of approximately 0.6 ml (delivering 0.3 ml to each catheter)
were forcibly administered at four minute intervals until flow
could be detected within the graft. The return of flow was
determined by frequent palpation of the graft to detect the
presence and distribution of the pulse, or occasionally by
Doppler. When flow was present throughout the graft, the
catheters were removed and the next step of the procedure was
initiated.
In the M group 10 ml of saline containing 2,000 U of heparin
was used for lysis. This was pulsed into the catheters in 0.6 ml
volumes in the same manner using rapid, very forceful pulses.
Following this process, the pulse-spray catheters were removed
and the procedure was continued. At this point flow was
generally present, but was not considered essential. Complete
thrombolysis was not a goal in either group at this point. In the
PM group, the return of flow was the end point for pulsing. In
the M group there was no prerequisite for proceeding with the
procedure, it was automatic.
After removing the pulse-spray catheters, the angioplasty
balloon catheter was inserted and the entire length of the graft
was dilated to macerate residual clot and dilate any stenosis that
was present within the graft. A 5F sheath was inserted at the
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former site of the arterial pulse-spray catheter. Through this
sheath a 4F arterial embolectomy catheter (Fogarty, Baxter
Healthcare Inc.) 40 cm in length was inserted. This was passed
across the arterial anastamosis, inflated using a 1 ml contrast-
filled syringe and pulled back through the entire length of the
graft up to the point of insertion of the sheath. Only gentle
pressure was used until the arterial anastamosis was crossed,
then firm pressure was applied within the graft. If flow through
the graft did not appear to be optimum at this point, the
procedure with the embolectomy balloon was repeated several
times. If flow was still poor, the arterial anastamosis was
visualized angiographically. In the cases with stenosis of the
arterial anastamosis, a 4 mm angioplasty balloon catheter was
placed across the anastaniosis using a guide wire. The stenosis
was dilated, then the embolectomy catheter was used again. At
the end of the procedure, the venous end of the graft was
flushed with saline.
An angiogram was performed at this point to verify that the
graft was clear of thrombus and that any stenotic lesions
previously present had been dilated. If the angiographic appear-
ance was satisfactory, all objects were removed from the graft
and digital pressure was applied to the two graft puncture sites
using thrombin (Thrombostat, Park-Davis, Morris Plains, New
Jersey, USA) soaked gelatin sponge (Gelfoam, Upjohn Co.,
Kalamazoo, Michigan, USA). Hemostasis generally required
two to five minutes.
A record was maintained of the time required to perform each
combined procedure (angiogram, thrombolysis and angio-
plasty). This time did not include the time required to prepare
and drape the patient's arm, and it did not include the time
required for hemostasis at the end of the procedure. In all
instances the procedures were performed in the angiography
suite on an outpatient basis. Following the procedure most
patients were sent directly to dialysis.
Patient evaluation
Each case was evaluated for complications of the lytic
enzyme, evidence of distal embolization beyond the arterial
anastamosis, and clinical evidence of pulmonary embolization.
This evaluation was performed immediately and was continued
in the dialysis unit as the patients were followed on dialysis
subsequent to the treatment. Chest x-rays were not routinely
done. In addition, each case had long-term follow-up to deter-
mine the duration of patency of the graft following the com-
bined procedure. The history of each patient's access graft was
reviewed to determine its age, if any procedure had been
previously performed on the graft and the duration of patency
of such previous therapy.
Criteria for success
A distinction was made between success of the combined
procedure, thrombolysis and angioplasty, and the thrombolysis
procedure alone. The combined procedure was considered
successful if the thrombus could be lysed and unobstructed flow
through the graft and draining veins could be established
sufficiently and persistently enough to allow for one subsequent
normal dialysis. Thrombolysis was counted as successful if the
thrombus could be lysed and eliminated as determined angio-
graphically. The period of time which elapsed until the graft
thrombosed again or required another invasive procedure such
as surgical revision or angioplasty was counted as the duration
of patency of the combined procedure.
Statistical analysis
The Kaplan-Meier method was used to calculate the life table
analysis data. Comparisons of long-term patency for the differ-
ent groups were made using the generalized Wilcoxon test for
comparing data derived from life table analysis involving cen-
sored observations. To compare the differences in time required
to perform the combined procedure in the two groups, the
Wilcoxon rank sum test was applied. The Spearman rank
correlation test was used to compare the differences in duration
of patency between paired groups. The chi-square test was
utilized to determine the statistical significance of differences in
the incidence of several different variables noted between the
two groups. Correlation coefficients were calculated using the
least squares method. In all instances a probability value of 0.05
or less was used to determine statistical significance.
Results
A total of 104 cases of thrombosed vascular access grafts in
78 patients were entered into the study over a period of seven
months. Several patients had more than one episode (maximum
of 4). Random distribution of the cases resulted in 49 cases in
the PM group and 55 cases in the M group. In only one case was
the procedure not initiated because of an inability to pass the
guide wire across an area of venous occlusion above the graft.
This case had been randomized to the PM group, but was
dropped from the study leaving 48 cases in this group. In the
remaining 103 cases the procedure appropriate for the group
was performed. Since the thrombotic event for each patient
generally occurred at some time between regularly scheduled
treatments and was not recognized until the patient presented
for dialysis, the age of the thrombosis at the time of the
procedure was not precisely known. For most patients it was
less than 44 hours old where the interdialytic interval was 48
hours, and less than 68 hours old when the interval was 72
hours. In one case in the PM group the graft had been
thrombosed for four days and in one patient in the M group the
graft had been occluded for 13 days. Except for these two cases
the thrombolytic procedure was performed on the same day
that the thrombosed graft was identified, generally within a
matter of one to two hours. In many cases it was possible to
have the patient back on dialysis within two to three hours of
the diagnosis of a clotted graft. Within the M group, 27 cases
had straight grafts and 28 had loops. Three of the loops were in
the upper arm and one was in the thigh. Within the PM group,
20 cases had straight grafts and 28 had loops (Table 2). Of the
loops, three were in the upper arm. These differences were not
significant (P = 0.543).
Although thrombolysis successfully removed the thrombus in
100% of the cases in both groups (Table 3), the overall success
rate for the combined procedure was 92.8% in the M group and
93.8% in the PM group. The difference in these two numbers
was because flow could not be restored in four cases (7.2%) of
the M group and three cases (6.2%) of the PM group. The
problem in each of these instances was the presence of a
stenotic lesion that could not be repaired by angioplasty. This
difference was not statistically significant (P = 0.832).
Venous stenotic lesions (Table 1) were present in 45 (93.8%)
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Table 2. Characteristics of groups
Category
Group
Mechanical Pharmacomechanical
Number 55 48
Agent Saline Urokinase
Venous stenosisa 93.8% 94.5%
Arterial stenosisa 9.1% 10.4%
Graft age monthsa
median 10.6 11.8
range 0,5 to 114.7 0.5 to 138
Graft type
straight 27 20
loop 28 28
a Differences between groups were not statistically significant (P =
0.532, 0.816, 1.00) for venous stenosis calculations were based upon
frequency and location of specific category of lesion
Table 3. Immediate results of therapy
Category
Group
Mechanical Pharmacomechanical
Thrombolysisa
FUflCtjofla.
100%
92,8%
100%
93.8%
Time requiredc 48 58
miii
Complications"
local 18% 10.4%
distal" 0% 0%
systemic 0% 0%
a The values listed refer to % successb No statistically significant difference was noted (P = 0.832, 0.264)
C The differences noted were statistically significant (P = 0.008)
"Refers to arterial embolization beyond the arterial anastamosis
of the PM cases and 53 (94.5%) of the cases of the M group. The
distribution of venous lesions for the M group was as follows:
within the graft 32.7%, venous anastamosis 69%, peripheral
venous 45.4%, central venous 5.4%. In 47.3% of these cases
lesions were present at more than one site. In the PM group the
distribution was: within the graft 39.6%, venous anastamosis
53.3%, peripheral venous 46.7%, central venous 4.6%. Lesions
were present in more than one of these locations in 22.9%.
Stenosis at the arterial anastamosis was present in five members
of each group. This represented 9.7% of the total patients
treated. None of these differences were significant (P = 0.532,
0.816).
The mean time required to perform the combined procedure
in the M group was 48 minutes (median 45) with a range of 24 to
88 minutes. In the PM group, the mean time required was 58
minutes (median 55) with a range of 30 to 135 minutes (Table 3).
The difference between the time required for the two groups
was statistically significant (P = 0.008). This difference in time
was due to the time delay between pulses in the PM group. The
mean dosage of urokinase used in the PM group was 140,000 IU
(median 135,000 IU) with a range of 100,000 to 250,000 IU. The
3 cc of urokinase used for the fill volume of the catheters was
included in this total.
No instance of peripheral embolization was observed and no
patient had any clinical suggestion of pulmonary embolization.
Local complications in the form of a small hematoma 2 cm by 4
Table 4. Long-term results of therapya
Days post-therapy
Group"
Mechanical Pharmacomechanical
15
30
60
90
74%
65%
58%
37%
77%
72%
62%
46%
a Refers to duration of patency following the combined procedure
(life table analysis)
"The differences noted between the groups were not significant (P =
0.17)
cm or less in size were seen in 10 cases of the M group and five
cases of the PM group (Table 2). These were all at fresh needle
puncture sites that had been created at the dialysis unit prior to
recognition that the graft was thrombosed. They did not result
in significant problems. The difference between the incidence of
these complications in the two groups was not statistically
significant (P = 0.264).
The age of the access grafts (Table 1) in the M group had a
mean of 22.6 months (median 10.6 months) with a range of 0.5
to 114.7 months. In the PM group the graft age had a mean of
21.4 months (median 11.8 months) with a range of 0.5 to 138
months. There was no significant difference between the two
groups (P = 1.00). In addition to the fact that the access had
been in place for only 15 days in one patient of each group,
several patients of each group had had an invasive procedure
less than 30 days prior to the study thrombolysis. In the M
group 10 patients had a surgical thrombectomy three to 11 days,
two had a surgical revision of their graft two and 14 days, and
two had a thrombolysis two and three days prior to the study
thrombolysis. In the PM group seven patients had a surgical
thrombectomy five to 25 days, two had a surgical revision at six
and 10 days, and six had prior thrombolysis from two to 28 days
prior to the their study thrombolysis. None of these was
associated with any adversity when the study thrombolysis was
performed.
The duration of patency (Table 4) for the combined procedure
in the M group was as follows: 15 days 74%, 30 days 65%, at 60
days 58% and at 90 days 37%. For the PM group the duration of
patency was: 15 days 77%, 30 days 72%; 60 days 62%; and at 90
days 46%. These values were determined by life table analysis.
A comparison of the data for the two groups revealed no
significant difference at any period (P = 0.17).
Most of these cases had had previous procedures performed
upon their grafts. The duration of patency for this previous
therapy was determined and compared to the duration of
patency observed in these cases following the combined proce-
dure. A general correlation was seen between the two variables
with a correlation coefficient of 0.312. Thirty-two of the cases in
the M group had had a surgical thrombectomy as the procedure
that immediately preceded the thrombotic event that was
treated by thrombolysis. A comparison of the duration of
patency for these two procedures (one surgical, the other
non-surgical) in the same patient revealed that there was no
statistically significant difference (P 0.30). The same compar-
isons in the PM group also showed no significant difference
(P = 0.30).
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Discussion
The availability to the nephrologist of a non-surgical tech-
nique to restore function to a thrombosed dialysis graft is an
attractive goal in view of the frequency of this problem, the cost
and frequent requirement for hospitalization, and the delay
often associated with surgical therapy. The ability to quickly
restore graft function in an outpatient setting in a safe, mini-
mally invasive manner which permits timely dialysis without
the need for central venous catheters would decrease costs,
benefit patient morale and decrease morbidity. With recent
improvements in the technique, thrombolysis could be a candi-
date for this position.
In the past 20 years, thrombolysis has undergone a significant
evolution [1—13]. The history of this procedure as applied to the
dialysis access started with techniques that were strictly pharma-
cological, involving infusion of high doses of lytic enzymes over
periods of time ranging from two [6] to 72 [3] hours. Hospitaliza-
tion was required, often within the intensive care unit. Success
rates as low as 14% [5] were reported with bleeding complications
as high as 57% [6], arterial embolization as high as 6% [8], allergic
complications as high as 40% [3] and total complications as high as
85.7% [5]. As late as 1989, a study involving 67 cases was reported
[9] in which the mean dose of urokinase used was 1,130,000 IU
over a mean time of 15.2 hours with an immediate failure rate of
42%. In 18% of the cases the failure was due to bleeding that
necessitated discontinuing the procedure, eight cases required
blood transfusions. From the nephrologist's viewpoint this
situation was impractical and unacceptable.
Recently, the major obstacles to effective and practical
percutaneous therapy of thrombosed dialysis access grafts have
been largely eliminated by the development of techniques to
accelerate thrombolysis using a combination of fibrinolytic
therapy with concentrated urokinase and mechanical clot mac-
eration and removal [10—13]. This technique, referred to as
pharmacomechanical thrombolysis (PMT), has yielded success
rates greater than 95% using much smaller doses of enzyme
with lysis times of 40 minutes or less with very few complica-
tions. Patients have been treated on an outpatient basis and
have been returned to dialysis within 30 minutes of completing
the procedure. The manner in which the treatment is accom-
plished allows for a combined procedure that involves angiog-
raphy and angioplasty to evaluate the graft's status and correct
not only the symptom (occlusion of the graft), but also the
disease (venous stenosis).
In evaluating this procedure in our unit, it was noted that in
several cases flow appeared within the graft very early, before
a significant amount of lytic enzyme had been administered. In
several cases flow was restored by simply inserting the cathe-
ters. This study was initiated to expand further on this obser-
vation and determine the effectiveness of using only the me-
chanical aspects of PMT to restore function to thrombosed
grafts without the benefits of the lytic agent.
Over a period of seven months 103 patients with thrombosed
PTFE grafts were studied in a controlled fashion with the cases
being randomly assigned to a mechanical (M) group and a
pharmacomechanical (PM) group. These groups were compa-
rable in every respect (Table 2). The M group received only
heparinized saline using crossed pulse-spray catheters while the
PM group received the conventional concentrated urokinase,
but with a slightly longer interval between pulses of enzyme
than use by others, four versus 0.5 minutes [10—13]. Both
groups were treated in an identical fashion except for the agent
pulsed through the catheters.
The immediate response to therapy in the two groups was
identical with 100% removal of the thrombus as defined by
angiography. The restoration of function, which is a measure of
the effectiveness of the combined procedure of thrombolysis
and angioplasty was 92.8% for the M group and 93.8% for the
PM group (Table 3). The difference between the rate of clot
removal and restoration of flow was due to the presence of
stenotic lesions that could not be treated with angioplasty.
These rates represent the actual success of the techniques used,
but the failures were not due to an inability to rid the graft of
thrombus. These number were very similar to the data reported
by Roberts et al [13], and is almost identical to that group's
earlier data reported by Vaiji et al [11]. We noted that a slightly
longer period was required for the PM group because of the
waiting time of four minutes between pulses of the enzyme.
Complications were all minor and caused no difficulty. No
arterial emboli or clinical evidence of pulmonary emboli were
noted in either group (Table 3). The long-term results (primary
patency) which are largely a reflection of the success of the
angioplasty procedure, were equivalent in the two groups
(Table 4) and were very similar to those reported by Valji et a!
[11] in their series of PMT.
With mechanical thrombolysis small thrombi are undoubt-
edly being released into the circulation. The possibility of
creating a dangerous pulmonary embolus has been a concern,
but has not been seen. Mechanical removal of an occluding
thrombus is not a totally new concept. Hunter et a! [15]
reported removing small thrombi using an angioplasty balloon
and Trerotola et al [16] have used this as the primary treatment
for thrombosed grafts. No clinical evidence of pulmonary
emboli was noted by these investigators. Even with pharmaco-
logical [2—91 and pharmacomechanical [10—14] techniques, as
flow returns, it is probable that small pieces of residual clot are
being detached and carried centrally. This is especially likely to
occur during the mechanical phase of PMT, since its advocates
do not hesitate to begin the use of the angioplasty balloon within
the graft despite the continued presence of residual mural
thrombi [9—11]. Additionally, a platelet rich thrombus (white
thrombus) is frequently present just upstream from the arterial
anastamosis [11, 13, 17]. Roberts et al [13] reported the pres-
ence of this thrombus in 84 of 200 cases. This thrombus is
resistant to fibrinolysis necessitating its mechanical removal
with a balloon catheter as part of the PMT technique. In spite of
the possibilities for pulmonary emboli, review of a cumulative
total of over 650 cases of thrombolysis reported in the literature
[2—13] reveals only one case of clinically evident pulmonary
embolus [71, the symptoms of which were gone within 24 hours,
and two cases of transient chest pain of undetermined etiology
[11]. No clinical evidence to suggest pulmonary embolism was
seen in any of the cases in this report. Even in those cases with
repeated throinbolysis, no adverse sequelae were noted.
There are several observations that have been made by other
investigators that were confirmed and extended in this report.
The age of the graft [9] does not have any effect on the success
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of thrombolytic therapy. The incidence of venous stenosis [9,
111 is greater than 90%, a figure significantly higher than that in
surgical reports where angiography was not used. The duration
of patency for the procedure that preceded the thrombolysis [9]
correlated with the long-term patency of the graft following
thrombolysis. A correlation coefficient of 0.312 was seen when
the two were compared. In those cases in which a surgical
thrombectomy had been done previous to the event treated by
thrombolysis, no significant difference in duration of patency
was seen for the two procedures in the same patients. This
suggests that factors intrinsic to the patient and independent of
the type of therapy may be important in determining duration of
patency. Controlled studies are needed to further illuminate this
issue.
The difficulty of prolonged bleeding from needle puncture
sites reported by others was solved in this study by using a
thrombin soaked gelatin sponge. Hemostasis was obtained in
two to five minutes. The explanation for the need for signifi-
cantly less urokinase in this study than has been reported by
others [11—13] is not apparent. The possibility that the longer
interval between pulses of lytic agent giving more time for
enzymatic activity to take place must be considered as a
possibility. Also, the criteria that have been used to determine
when to terminate urokinase pulsing and proceed with the
remainder of the procedure have not been made clear in these
previous reports. In this study, when flow appeared, urokinase
pulsing was discontinued. It seemed apparent that any further
agent administered would be washed away by the flow and not
be present at the site necessary for lytic action to take place.
In conclusion, mechanical thrombolysis using a macerating
pulse of heparinized saline generated by crossed pulse-spray
catheters followed by balloon maceration and dilation is as
effective and safe to use for the treatment of thrombosed
dialysis access grafts as pharmacomechanical thrombolysis. It
has the advantage over pharmacomechanical thrombolysis of
avoiding the cost of the lytic agent.
Reprint requests to Gerald A. Beathard, M.D., Ph.D., 801 West 34th
Street, Austin, Texas 78705, USA.
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